Original Research
Published on 19 Oct 2022
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
in Drug Metabolism and Transport
- 3,659 views
- 10 citations